<?xml version="1.0" encoding="UTF-8"?>
<results title="test_trace">
 <result pre="The management of these patients makes it necessary to reconcile" exact="infection" post="protocols (e.g., isolation), with needs that are intrinsic to"/>
 <result pre="to create hemodialysis rooms, intended partially for patients with SARS-CoV-2" exact="infection" post="and partially for patients who are negative for SARS-CoV-2"/>
 <result pre="peak of the COVID pandemic 1st Floor Inpatients with COVID-19" exact="infection" post="receiving hemodialysis17 beds Hemodialysis room for inpatients with COVID-19"/>
 <result pre="infection receiving hemodialysis17 beds Hemodialysis room for inpatients with COVID-19" exact="infection" post="Hemodialysis rooms for inpatients who are negative for COVID-19"/>
 <result pre="are negative for COVID-19 Dialysis room for inpatients with COVID-19" exact="infection" post="or suspected cases Inpatients with COVID-19 who received transplantation12"/>
 <result pre="the patients with CKD. To date, no patients on immunosuppressive" exact="treatment" post="due to primary or secondary glomerulonephritis have been admitted"/>
 <result pre="imputable to SARS-CoV-2 infection; these patients were advised to respect" exact="social distancing" post="rules since the early stages of the coronavirus crisis."/>
 <result pre="average of 13 days. We admitted 21 patients with COVID-19" exact="infection" post="receiving hemodialysis, including 5 patients who died and 4"/>
 <result pre="and to date there are no approved drugs for the" exact="treatment" post="of SARS-CoV-2 infection.5 Although anecdotal experience can be drawn"/>
 <result pre="transplant patients in particular.6 The pharmacological approach to treating SARS-CoV-2" exact="infection" post="can be viewed as a 2-phase approach. The first"/>
 <result pre="however, a recent analysis failed in showing benefit with lopinavir/ritonavir" exact="treatment" post="beyond standard care in hospitalized adult patients with severe"/>
 <result pre="example, baseline characteristics suggest a higher disease severity in the" exact="treatment" post="arm (more patients with respiratory rate &amp;gt;24/min, with days"/>
 <result pre="cells.7 Azithromycin A small study performed on patients with COVID-19" exact="infection" post="and treated with hydroxychloroquine demonstrated that combination with azithromycin"/>
 <result pre="significant impact on the survival curves of patients with COVID-19" exact="infection" post="who have developed acute respiratory distress syndrome.16 Tocilizumab In"/>
 <result pre="contraindications. Clinical Patient Management and Monitoring Patients with known COVID-19" exact="infection" post="receive a chest X-ray at baseline and repeated when"/>
 <result pre="heparin and low-dose aspirin should be considered. During this phase," exact="treatment" post="with glucocorticoid and the interleukin-6 inhibitor tocilizumab should be"/>
 <result pre="oxygen levels with repeat arterial blood sampling, of the blood" exact="tests" post="including ferritin–coagulation–liver enzymes, and of the chest X-ray. We"/>
 <result pre="enzymes, and of the chest X-ray. We have formulated a" exact="treatment" post="protocol based on patient characteristics, phase of illness, and"/>
 <result pre="patients receiving hemodialysis and who underwent transplantation with a SARS-CoV-2" exact="infection" post="can be found in the Supplementary Appendix S1. We"/>
 <result pre="the Supplementary Appendix S1. We also provide further considerations for" exact="diagnosis" post="and treatment of these patients in the Supplementary Appendix"/>
 <result pre="Appendix S1. We also provide further considerations for diagnosis and" exact="treatment" post="of these patients in the Supplementary Appendix S2. Appendix"/>
 <result pre="2020 5World Health Organization. Clinical management of severe acute respiratory" exact="infection" post="when COVID-19 is suspected. Available at: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. Accessed March"/>
 <result pre="and Health Commission of Guangdong Province for chloroquine in the" exact="treatment" post="of novel coronavirus pneumonia[Expert consensus on chloroquine phosphate for"/>
 <result pre="of novel coronavirus pneumonia[Expert consensus on chloroquine phosphate for the" exact="treatment" post="of novel coronavirus pneumonia]Zhonghua Jie He He Hu Xi"/>
 <result pre="review on the efficacy and safety of chloroquine for the" exact="treatment" post="of COVID-19 [e-pub ahead of print]. J Crit Care."/>
 <result pre="a recommendation to examine the effect of hydroxychloroquine in preventing" exact="infection" post="and progression [e-pub ahead of print]. J Antimicrob Chemother."/>
 <result pre="JC, Parola P, et al. Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trial"/>
 <result pre="beta against MERS-CoVNat Commun11202022231924756 15de WitE.FeldmannF.CroninJ.Prophylactic and therapeutic remdesivir (GS-5734)" exact="treatment" post="in the rhesus macaque model of MERS-CoV infectionProc Natl"/>
 <result pre="who have a SARS-CoV-2 infection. Appendix S2. Further considerations for" exact="diagnosis" post="and treatment."/>
</results>
